Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06017622 · ClinicalTrials.gov registry record
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
A clinical trial of Acute Cannabis-induced CNS Depression, sponsored by Anebulo Pharmaceuticals.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT06017622: Recruiting study of Acute Cannabis-induced CNS Depression, sponsored by Anebulo Pharmaceuticals.
NCT06017622 is a study of Acute Cannabis-induced CNS Depression that is actively recruiting participants, run by Anebulo Pharmaceuticals. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06017622, a study of Acute Cannabis-induced CNS Depression, is actively recruiting participants, sponsored by Anebulo Pharmaceuticals.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
Primary Outcome
Concentration of THC and THC metabolites (11-OH-THC and THC-COOH) in plasma of subjects admitted to emergency departments due to acute cannabis induced CNS depression.
Conditions Studied
Study Locations (1)
Massachusetts
- University of Massachusetts Memorial Children's Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-12-30 |
What NCT06017622 shows while recruiting
NCT06017622 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 1 condition, with Acute Cannabis-induced CNS Depression appearing as the primary indexed condition, and to 0 interventions.
NCT06017622 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06017622 about?
NCT06017622 is a clinical study titled "Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression". This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
What is the current status of trial NCT06017622?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2023-06-01. Estimated completion is 2026-12-30.
What conditions does trial NCT06017622 study?
This clinical trial studies the following conditions: Acute Cannabis-induced CNS Depression.
Who is sponsoring clinical trial NCT06017622?
This trial is sponsored by Anebulo Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06017622 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI